视网膜疾病治疗市场规模、份额、成长分析、按疾病、按疾病类型、按治疗技术、按给药途径、按最终用户、按分销渠道、按地区 - 行业预测，2024-2031

2023年视网膜疾病治疗市场规模为125.7亿美元，从2024年的137.4亿美元成长到2032年的280.8亿美元，预测期间内(2025-2032)的复合年增长率为9.3%。

视网膜疾病的盛行率在全球范围内不断增加，影响了超过 2.53 亿人，并对医疗保健系统构成了重大挑战，尤其是随着人口老化。 81% 的受影响者年龄超过 50 岁，预期寿命的延长导致眼部护理领域的需求不断增加。视网膜疾病，特别是糖尿病性视网膜病变和糖尿病黄斑部水肿的发生率正在迅速增加，特别是在糖尿病盛行率不断增加的新兴国家。预计市场在预测期内将扩大，部分原因是可用于治疗这些疾病的专业人员数量不断增加。此外，到 2028 年，报销政策的加强预计将支持与视网膜疾病治疗相关的高成本，并推动市场成长。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 抑制因素和挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析

视网膜疾病治疗市场规模：依疾病分类

• 市场概况
• 黄斑部病变
• 糖尿病眼科疾病
• 视网膜剥离
• 视网膜母细胞瘤
• 黄斑皱纹
• 黄斑裂孔
• 漂浮者

视网膜疾病治疗市场规模：依疾病类型划分

• 市场概况
• 遗传的
• 年龄相关

视网膜疾病治疗市场规模：依治疗技术分类

• 市场概况
• 雷射
• 冷冻的
• 植入
• 缩排
• 气压式视网膜固定术
• 巩膜屈曲
• 玻璃体切除手术

视网膜疾病治疗市场规模：依给药途径划分

• 市场概况
• 口服
• 局部的
• 玻璃体内
• 其他的

视网膜疾病治疗市场规模：依最终用户划分

• 市场概况
• 医院
• 门诊手术中心
• 家庭保健
• 其他的

视网膜疾病治疗市场规模：依通路划分

• 市场概况
• 直接竞标
• 医院药房
• 零售药房
• 网路药房
• 其他的

视网膜疾病治疗的市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2022-2024）

主要企业简介

• Regeneron Pharmaceuticals, Inc.（USA）
• Roche Holding AG（Switzerland）
• Novartis AG（Switzerland）
• Allergan（part of AbbVie）（USA）
• Bayer AG（Germany）
• Oculis（Switzerland）
• REGENXBIO Inc.（USA）
• Adverum Biotechnologies, Inc.（USA）
• Kodiak Sciences Inc.（USA）
• EyePoint Pharmaceuticals, Inc.（USA）
• Apellis Pharmaceuticals, Inc.（USA）
• Iveric Bio, Inc.（USA）（Acquired by Astellas）
• Annexon Biosciences（USA）
• Hemera Biosciences（USA）（Acquired by Roche）
• Gyroscope Therapeutics（UK）（Acquired by Novartis）
• Graybug Vision, Inc.（USA）
• Clearside Biomedical, Inc.（USA）
• Ocuphire Pharma, Inc.（USA）
• Lineage Cell Therapeutics, Inc.（USA）
• Ocugen, Inc.（USA）

结论和建议

Retinal Disease Therapeutics Market size was valued at USD 12.57 Billion in 2023 and is poised to grow from USD 13.74 Billion in 2024 to USD 28.08 Billion by 2032, growing at a CAGR of 9.3% during the forecast period (2025-2032).

The prevalence of retinal disorders is escalating globally, impacting over 253 million people and posing significant challenges for healthcare systems, particularly as the population ages. With 81% of individuals affected being over 50, the rising life expectancy is intensifying demand in the ophthalmic care sector. The incidence of retinal diseases, notably diabetic retinopathy and diabetic macular edema, is surging, especially in developing countries where diabetes rates are increasing. The market is anticipated to expand during the forecast period, driven by the growing number of specialized professionals capable of addressing these conditions. Furthermore, enhanced reimbursement policies are expected to facilitate market growth by 2028, assisting with the high costs associated with retinal disease treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Retinal Disease Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Retinal Disease Therapeutics Market Segmental Analysis

Global Retinal Disease Therapeutics Market is segmented by disorder, disorder type, treatment techniques, route of administration, end-users, distribution channel and region. Based on disorder, the market is segmented into macular degeneration, diabetic eye disease, retinal detachment, retinoblastoma, macular pucker, macular hole and floaters. Based on disorder type, the market is segmented into genetic and age related. Based on treatment techniques, the market is segmented into laser, freezing, implanting, indenting, pneumatic retinopexy, scleral buckling and vitrectomy. Based on route of administration, the market is segmented into oral, topical, intravitreal and others. Based on end-users, the market is segmented into hospitals, ambulatory surgical centers, home healthcare and others. Based on distribution channel, the market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Retinal Disease Therapeutics Market

The growth of the retinal disease therapeutics market is significantly influenced by the rising prevalence of eye disorders, especially in developed nations. Notably, the American Academy of Ophthalmology reported that as of 2016, around 93 million people globally were affected by diabetic retinopathy, with 4.2 million cases in the United States alone. Projections by the NCBI estimate that by 2040, Europe could see between 14.9 to 21.5 million individuals with early Age-Related Macular Degeneration (AMD) and up to 4.8 million with late-stage AMD. Efforts to raise awareness about eye health and encourage early treatment, particularly in developing regions, are expected to further propel the growth of the retinal disease therapeutics market in the upcoming years.

Restraints in the Retinal Disease Therapeutics Market

The growth of the Retinal Disease Therapeutics market faces several challenges, primarily due to the high costs associated with treatment options for retinal diseases. The financial burden of these therapies can deter patients from seeking necessary care. Furthermore, patients often report experiencing short-term side effects, as well as potential long-term issues like infections and inflammation following procedures like laser eye surgery. Surgical techniques, such as pneumatic retinopexy, carry risks, including unintended scleral perforation, which may further influence patient choices. Additionally, inadequate healthcare infrastructure in developing countries poses significant barriers to market expansion, limiting access to effective therapies.

Market Trends of the Retinal Disease Therapeutics Market

The retinal disease therapeutics market is witnessing a significant upward trend, fueled by the emergence of advanced technologies such as gene therapy. Innovations like Luxturna, targeting inherited retinal disorders through RPE65 gene mutations, exemplify the progress being made in this field. As numerous gene therapies involving recombinant viral vectors advance through clinical trials, their potential to ameliorate conditions like Leber's congenital amaurosis is garnering attention and investment. Between 2022 and 2028, this focus on high-end therapeutic solutions is expected to drive market growth, paving the way for improved treatment outcomes and enhanced quality of life for patients suffering from retinal diseases.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Retinal Disease Therapeutics Market Size by Disorder & CAGR (2025-2032)

• Market Overview
• Macular Degeneration
• Diabetic Eye Disease
• Retinal Detachment
• Retinoblastoma
• Macular Pucker
• Macular Hole
• Floaters

Global Retinal Disease Therapeutics Market Size by Disorder Type & CAGR (2025-2032)

• Market Overview
• Genetic
• Age Related

Global Retinal Disease Therapeutics Market Size by Treatment Techniques & CAGR (2025-2032)

• Market Overview
• Laser
• Freezing
• Implanting
• Indenting
• Pneumatic Retinopexy
• Scleral Buckling
• Vitrectomy

Global Retinal Disease Therapeutics Market Size by Route Of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Topical
• Intravitreal
• Others

Global Retinal Disease Therapeutics Market Size by End-Users & CAGR (2025-2032)

• Market Overview
• Hospitals
• Ambulatory Surgical Centers
• Home Healthcare
• Others

Global Retinal Disease Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Direct Tender
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Retinal Disease Therapeutics Market Size & CAGR (2025-2032)

• North America (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
  • US
  • Canada
• Europe (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Regeneron Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan (part of AbbVie) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oculis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• REGENXBIO Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adverum Biotechnologies, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kodiak Sciences Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EyePoint Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Apellis Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iveric Bio, Inc. (USA) (Acquired by Astellas)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Annexon Biosciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hemera Biosciences (USA) (Acquired by Roche)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gyroscope Therapeutics (UK) (Acquired by Novartis)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Graybug Vision, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clearside Biomedical, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocuphire Pharma, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lineage Cell Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocugen, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations